权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel Approach to Facilitate Decisions in Patients w/ Muscle Invasive Bladder CA

促进肌肉侵袭性膀胱 CA 患者决策的新方法

基本信息

批准号：
9057990
负责人：
Michael A Diefenbach
金额：
$ 19.73万
依托单位：
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-05-01 至 2018-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9057990
关键词：
Address Adoption Belief Benefits and Risks Bladder Cancer Advocacy Cancer Patient Cancer Survivor Cisplatin Clinical Trials Combination Drug Therapy Communication Complex Consultations Counseling Cystectomy Data Decision Aid Decision Making Development Disease Effectiveness Feasibility Studies Focus Groups Goals Individual Internet Knowledge Malignant Neoplasms Malignant neoplasm of urinary bladder Measurement Medical Oncologist Meta-Analysis Modeling Muscle Neoadjuvant Therapy Newly Diagnosed Oncologist Online Systems Operative Surgical Procedures Pamphlets Patient Education Patient risk Patients Physicians Prior Chemotherapy Probability Process Protocols documentation Public Health Radical Cystectomy Randomized Clinical Trials Randomized Controlled Trials Recruitment Activity Recurrence Research Resources Risk Site Statistical Models Structure Surveys Survivors Testing Training Universities Urologist base chemotherapy clinical practice design evidence base expectation high risk illness perceptions improved innovation insight mortality novel strategies population based post intervention preference prognostic public health relevance risk perception satisfaction shared decision making standard care survival prediction tool uptake usability

项目摘要

DESCRIPTION (provided by applicant): Radical cystectomy (RC) is standard treatment for patients with muscleinvasive bladder cancer (MIBC). Level I evidence in the form of two randomized clinical trials and a metaanalysis have demonstrated an improvement in survival with the integration of neoadjuvant cisplatinbased combination chemotherapy (NC). Yet, a recent populationbased study demonstrated that only 1.2% of patients receive NC. Barriers to NC uptake are a) a lack of a tool predicting survival benefits with neoadjuvant therapy; and b) lack of evidencebased protocols to communicate complex data about the risks and benefits of such therapy. To address these issues, we have recently developed a model to predict survival in patients with MIBC treated with surgery based on commonly available preoperative variables. While such a model is the first critical step for decision making, there is a paucity o data on what type of information patients need to make a decision, along with how this individualized prognositic information would be best conveyed and integrated into the patientphysician consultation process. Thus, the specific aims are: Specific Aim 1: To develop and refine a counseling protocol consisting of a webbased risk prediction tool and two educational brochures, one for patients and one for physicians. Two focus groups (FG) will provide insights about MIBC survivors' information needs and preferences. 1 FG with physicians will explore barriers to recommending NC. An Internet survey with physicians through the Bladder Cancer Advocacy Network will identify additional barriers. Results will be incorporated in the content and layout of the educational brochures and the risk prediction tool. Usability of the risk prediction tool and content of the brochures will be evaluated by physicians (Urologists (n=5) and medical oncologists (n=5)) and patients (n = 10). Specific Aim 2a): To train urologists and oncologists in the use of the counseling protocol. During a 30min training session, physicians will be introduced in the use of the riskprediction tool and the physician brochure and be educated about appropriate risk communication principles. Aim 2b) To evaluate acceptability and feasibility of the counseling protocol with physicians and MIBC survivors. Newly diagnosed MIBC patients eligible for NC (N = 36), recruited in equal numbers from two study sites (Mount Sinai & Duke University), will participate in the counseling protocol. Pre and postintervention measurements will assess patients' risk perception, satisfaction with patientphysician communication, and decision making variables. The present research has the potential to significantly impact and change clinical practice through the integration of a structured risk communication protocol into the patient physician consultation. It is innovative, a it is the first of its kind to combine an evidencebased risk prediction tool with patient educatin into a physicianpatient counseling protocol for patients with MIBC.

描述（由申请人提供）：根治性膀胱癌（RC）是肌层浸润性膀胱癌（MIBC）患者的标准治疗。两项随机临床试验和一项荟萃分析的I级证据表明，新辅助顺铂联合化疗（NC）可改善生存率。然而，最近的一项基于人群的研究表明，只有1.2%的患者接受NC。 NC摄取的障碍是a）缺乏预测新辅助治疗的生存益处的工具;和B）缺乏基于证据的方案来传达关于这种治疗的风险和益处的复杂数据。为了解决这些问题，我们最近开发了一个模型，根据常用的术前变量预测手术治疗MIBC患者的生存率。虽然这样的模型是决策的第一个关键步骤，但是关于患者需要什么类型的信息来做出决策，以及如何最好地传达这种个性化的诊断信息并将其整合到患者与医生的咨询过程中的数据沿着。因此，具体目标是：具体目标1：制定和完善一个咨询协议，包括一个基于网络的风险预测工具和两个教育手册，一个是病人，一个是医生。两个焦点小组（FG）将提供有关MIBC幸存者的信息需求和偏好的见解。 1 FG与医生将探讨推荐NC的障碍。通过膀胱癌宣传网络与医生进行的互联网调查将确定其他障碍。评估结果将纳入教育手册和风险预测工具的内容和布局。风险预测工具的可用性和手册的内容将由医生（泌尿科医生（n = 5）和医学肿瘤学家（n = 5））和患者（n = 10）进行评价。具体目标2a）：培训泌尿科医生和肿瘤科医生使用咨询方案。在30分钟的培训课程中，将向医生介绍风险评估预测工具和医生手册的使用，并就适当的风险沟通原则进行教育。目标2b）与医生和MIBC幸存者一起评估咨询方案的可接受性和可行性。符合NC条件的新诊断MIBC患者（N = 36），从两项研究中招募相同数量的患者地点（西奈山和杜克大学），将参加咨询协议。介入治疗前后的测量将评估患者的风险感知、患者与医生沟通的满意度以及决策制定变量。本研究有可能通过将结构化风险沟通协议整合到患者医生咨询中来显著影响和改变临床实践。它是创新的，它是第一个将基于证据的风险预测工具与患者教育结合起来的联合收割机，用于MIBC患者的医生-患者咨询协议。

项目成果

期刊论文数量（8）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Trends in the use of cytoreductive nephrectomy in the United States.

美国细胞减灭术的使用趋势。

DOI：
10.1016/j.clgc.2012.03.008
发表时间：
2012
期刊：
Clinical genitourinary cancer
影响因子：
3.2
作者：
Tsao,Che-Kai;Small,AlexanderC;Moshier,ErinL;Gartrell,BenjaminA;Wisnivesky,JuanP;Sonpavde,Guru;Godbold,JamesH;Palese,MichaelA;Hall,SimonJ;Oh,WilliamK;Galsky,MatthewD
通讯作者：
Galsky,MatthewD

Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.

DOI：
10.1007/s00345-012-1001-3
发表时间：
2013-12
期刊：
World journal of urology
影响因子：
3.4
作者：
Tsao CK;Small AC;Kates M;Moshier EL;Wisnivesky JP;Gartrell BA;Sonpavde G;Godbold JH;Palese MA;Hall SJ;Oh WK;Galsky MD
通讯作者：
Galsky MD

The follicle-stimulating hormone receptor: a novel target in genitourinary malignancies.

促卵泡激素受体：泌尿生殖系统恶性肿瘤的新靶点。

DOI：
10.1016/j.urolonc.2012.03.005
发表时间：
2013-11
期刊：
Urologic oncology
影响因子：
0
作者：
Gartrell BA;Tsao CK;Galsky MD
通讯作者：
Galsky MD

Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States.

美国 I 期肾癌保留肾单位手术的使用趋势和变化。

DOI：
10.1007/s00345-012-0873-6
发表时间：
2013
期刊：
World journal of urology
影响因子：
3.4
作者：
Small,AlexanderC;Tsao,Che-Kai;Moshier,ErinL;Gartrell,BenjaminA;Wisnivesky,JuanP;Godbold,James;Sonpavde,Guru;Palese,MichaelA;Hall,SimonJ;Oh,WilliamK;Galsky,MatthewD
通讯作者：
Galsky,MatthewD

Emerging personalized approaches for the management of advanced urothelial carcinoma.

治疗晚期尿路上皮癌的新兴个性化方法。